DepoMed (DEPO) Showing Signs Of Perilous Reversal Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified DepoMed ( DEPO) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified DepoMed as such a stock due to the following factors:

  • DEPO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $25.0 million.
  • DEPO has traded 1.3 million shares today.
  • DEPO is down 3% today.
  • DEPO was up 5.3% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in DEPO with the Ticky from Trade-Ideas. See the FREE profile for DEPO NOW at Trade-Ideas

More details on DEPO:

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. DEPO has a PE ratio of 13. Currently there are 5 analysts that rate DepoMed a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for DepoMed has been 1.5 million shares per day over the past 30 days. DepoMed has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.42 and a short float of 23.7% with 11.36 days to cover. Shares are up 45.6% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO